Financial insights of CYCCP

MyFinsight

For the quarter ending 2025-06-30.

Unit: Dollar

Income Statement	2025-06-30
Revenues	0
Revenues-Clinical Trial Supply	0
Research and development	68,000
General and administrative	1,249,000
Total operating expenses	1,317,000
Operating loss	-1,317,000
Other income, net	2,000
Interest income	2,000
Foreign exchange losses	-3,000
Gain on deconsolidation of subsidiary	0
Total other income (expense), net	1,000
Loss before taxes	-1,316,000
Income tax benefit	2,000
Net loss	-1,318,000
Dividend on convertible exchangeable preferred shares	20,000
Net loss applicable to common shareholders	-1,338,000

Net loss per share, basic	-0.98
Net loss per share, diluted	-0.98